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Dominant mutations in the surfactant protein-C(SFTPC) gene have been linked with interstitial
lung disease. The frequency of lung disease due to SFTPC mutations in the general population
is unknown. The aim of this study was to identify novel SFTPC mutations that are associated
with lung function or disease in the general population.
We resequenced the SFTPC gene in 760 individuals and identified 18 genetic variants, of
which 5 were novel. Of the five novel mutations, two were situated in highly conserved areas
of the SFTPC gene: A53T and Y106X. We genotyped the Copenhagen City Heart
Study(nZ 10,604) and the Copenhagen General Population Study(nZ 37,337) to assess the
clinical relevance of these mutations.
Genotyping identified 36 individuals heterozygous for A53T and 3 individuals heterozygous
for Y106X. A53T heterozygotes and Y106X heterozygotes did not differ from non-carriers in
FEV1% predicted, FVC% predicted or FEV1/FVC. A53T heterozygotes had a two-fold increased
risk for asthma in the Copenhagen City Heart Study and Copenhagen General Population Study
combined (adjusted odds ratio 2.2(1.0e4.9)). A53T heterozygotes did not differ consistently
from non-carriers in risk of chronic obstructive pulmonary disease or interstitial lung disease.
No Y106X heterozygotes suffered from asthma, chronic obstructive pulmonary disease (COPD),
or interstitial lung disease.
We identified two novel mutations in highly conserved areas of the SFTPC gene, and showt of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Faculty of Health
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Mutations in SP-C and obstructive lung disease 419that heterozygotes for the mutations have normal lung function and are unaffected by COPD
and interstitial lung disease. A53T heterozygotes had increased asthma risk, but further
research is required to conclusively determine whether this mutation is associated with
asthma.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The lung surfactant consists of phospholipids, cholesterol,
and proteins and is primarily produced by alveolar type II
cells.1,2 It forms a thin lipid layer on the surface of alveoli,
which reduces surface tension and prevents alveoli from
collapse during expiration. Upon exocytosis from alveolar
type II cells, surfactant initially exists as multilayered
vesicular structures in the epithelial lining fluid. From these
structures it spreads to the surface as alveoli are extended
and compressed during breathing. Insufficient function of
surfactant in preterm babies can cause collapse of alveoli
and respiratory distress syndrome, while inherited defi-
ciencies have been linked with respiratory distress
syndrome in term infants and interstitial lung disease in
older infants and adults.3,4
Surfactant protein-C (SP-C) (OMIM 178620) is one of four
surfactant proteins expressed exclusively in alveolar type II
cells.5 SP-C is important for the function of surfactant as it
enhances adsorption of lipids to the upper monolayer and
stabilises protrusion formation during exhalation.6,7 In mice
with genetic deletion of SP-C, susceptibility for interstitial
lung disease, emphysema, and pseudomonas infection is
increased.8e10 In humans, mutations in SFTPC have been
linked with interstitial lung disease in children and
adults.4,5 At present more than 35 disease-associated
mutations in SFPTC have been identified.4,5,11e20 Intersti-
tial lung disease has only been identified in heterozygous
individuals, and thus disease-associated mutations in SFTPC
have been proposed dominant-negative, i.e. secretion of
normal SP-C is prevented by aggregation of mutated SP-C in
alveolar type II cells, followed by cell injury and inflam-
mation.14 Given the putative dominant-negative effects of
SFTPC mutations and the impact on severe lung phenotypes
in humans and mice, SP-C mutations could play an impor-
tant role on development of common pulmonary disorders
in individuals from the general population.
We hypothesised that subjects heterozygous for SFTPC
mutations have reduced lung function, and greater risk of
asthma, chronic obstructive pulmonary disease (COPD), or
interstitial lung disease in the general population. To test
this, we resequenced 760 individuals with extreme lung
phenotypes from a general population study, The Copen-
hagen City Heart Study. Performing this screening we
identified two novel mutations in highly conserved areas of
the SFTPC gene, the A53T and Y106X mutations. We then
genotyped all 10,604 individuals from The Copenhagen City
Heart Study and another 37,337 individuals from The
Copenhagen General Population Study for the two muta-
tions identified. Finally we tested whether individuals
heterozygous for the A53T and Y106X mutations had
reduced lung function, or greater risk of asthma, COPD, and
interstitial lung disease compared with non-carriers.Methods
Subjects
The study was approved by the local ethical committee:
Nos. 100.2039/91 and 01-421/94, Copenhagen and Freder-
iksberg committee. All participants gave written informed
consent. All participants were Caucasian of Danish descent.
The Copenhagen City Heart Study is a prospective
general population study of individuals selected based on
the Central Population Register Code to reflect the adult
Danish population aged 20 to 80þ years.21 The Copenhagen
City Heart Study was initiated in 1976e1978 with follow-up
examinations in 1981e1983, 1991e1994 and in 2001e2003.
DNA was isolated from participants attending the
1991e1994 (nZ 9252) and/or 2001e2003 examinations
(additional nZ 1352).
The Copenhagen General Population Study is an ongoing
population-based cohort study initiated in 2003.22 At the
time of genotyping for the present study, 37,337 individuals
had been included. Participants were selected based on the
Central Population Register Code to reflect the adult Danish
population aged 20 to 80þ years. Participants are recruited
from a different part of Copenhagen than the Copenhagen
City Heart Study and there is no overlap of individuals
between the two studies.
Information on lung function measurements and the
collection of diagnoses of lung disease are described in
detail in the Supplementary.Extreme lung phenotype screening
For the screening of the SFTPC gene, we selected those
individuals in the Copenhagen City Heart Study who had
extreme lung phenotypes, i.e. those with the highest forced
expiratory volume in first second (FEV1) % predicted
(nZ 140), lowest FEV1 % predicted among smokers
(nZ 122), lowest FEV1 % predicted among non-smokers
(nZ 118), earliest onset of asthma (nZ 174), earliest onset
of COPD (nZ 175), and interstitial lung disease (nZ 31).
Six PCR fragments were amplified, covering all 5 pro-
protein coding exons (exons 1e5) of SFTPC, the intron-exon
boundaries, and the promoter containing region (300 bp
region upstream of exon 1). The PCR reaction contained
15 ng of DNA pr reaction, 5 units/ml Taq polymerase
(BioTaq), 800 mM dNTP mixture, 2e4 mM MgCl2 and 0.25 mM
of each primer. Mutational screening analysis of the
amplicons was performed by Lightscanner (Idaho Tech-
nology). PCR fragments with DNA melting curves differing
from wild type control DNA were subsequently sequenced
on Megabace. Primer sequences, and PCR cycle and
sequencing conditions are listed in Supplementary.
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Copenhagen general population study
We used the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems Inc., Foster City, CA, USA) to genotype
the Copenhagen City Heart Study and the Copenhagen
General Population Study for the two novel mutations
identified by the extreme phenotype screening. TaqMan
based assays were used. All heterozygous findings were
validated by DNA sequencing.Statistical analysis
Statistical analysis was performed with STATA version 10.0.
For power calculations, NCSS-PASS was used. A two-sided
P< 0.05 was considered significant. Student’s t-test and
Pearson’s chi-square test were used for two-group
comparisons. To approach Gaussian distribution, FEV1/FVC
was cubed before statistical analysis. Risks for disease
according to SP-C genotype were determined by logistic
regression models. The regression models were adjusted for
age, sex and smoking status.Results
Table 1 shows the clinical characteristics of individuals
with extreme lung phenotypes identified in the Copenha-
gen City Heart Study. As would be expected, individuals
with early-onset asthma were younger and smoked less
than those without an extreme lung phenotype, while
individuals with early-onset COPD and interstitial lung
disease were older and smoked more compared with
controls. Individuals with early-onset asthma and
interstitial lung disease were also more likely females
than those without an extreme phenotype, whereas
individuals with early-onset COPD were more likely males
compared with controls. Individuals with high/low
pulmonary function did not differ in sex or age from those
without an extreme phenotype.Table 1 Clinical characteristics of individuals with extreme lun
Asthma
(nZ 174)
COPD
(nZ 175)
Interstitial
lung disease
(nZ 31)
Age, yrs 44 0.9 61 0.6 67 1.6
Male/Female, % 36/64 49/51 39/61
FEV1 % predicted 84 1.1 61 1.4 61 4.8
FVC % predicted 88 1.1 73 1.3 70 4.3
FEV1/FVC 0.78 0.01 0.66 0.01 0.69 0.03
Ever smokers, % 56 97 94
Pack years 8.6 1.2 34 1.8 39 7.9
Values represent mean  SEM or percentages. AsthmaZ yes to the q
Disease (COPD)Z FEV1/FVC< 0.7 and FEV1% predicted <80%, excl. a
FEV1Z the 140 individuals who had the highest FEV1% predicted in
individuals with the lowest FEV1% predicted among current smokers. L
predicted among ex-smokers and non-smokers.Genetic variation in the SFTPC gene
In order to identify new genetic variation in the SFTPC
gene, we resequenced 760 individuals with extreme lung
phenotypes. We identified eighteen genetic variants in the
SFTPC gene (Table 2).
Of these eighteen variants, nine were identified in the
protein coding region of SFTPC [c.413C> A (T138N),
c.557A>G (N186S), c.24C> G (pV8V), c.42G> A (P14P),
c.157G> A (A53T), c.162G> C (L54L), c.198G> A (E66E),
c288C> T (I96I), c.318C> A (Y106X)]. Four of the nine
variants in the protein coding region introduced either
amino acid substitution or truncation of the SFPTC transcript
and could be of potential functional relevance [c.157G> A
(A53T), c.318C> A (Y106X), c.413C> A (T138N), c.557A> G
(N186S)]. The T138N and N186S single nucleotide poly-
morphisms (SNPs) have been described previously and are
relatively common (Table 2). We did not examine these
variants in further detail. The A53T and Y106X mutations
have not been reported or described previously.
The A53T mutation substitutes nonpolar alanine for
polar threonine in exon 2 and is situated within the 35
amino acid sequence that constitutes the mature SP-C
protein. This region is highly conserved between species
(human, mouse, rat) (Fig. 1). The A53T mutation was
identified in two individuals, one belonging to the COPD
group and the other belonging to the low FEV1 nonsmoker
group. The other Y106X mutation introduces a premature
stop codon in exon 3, thereby truncating most of the
conserved BRICHOS domain, a domain shown to be associ-
ated with correct folding and processing of proSP-C.23 The
Y106X mutation was identified in one individual from the
low FEV1 nonsmoker group.
Three SNPs [271 G> A, 92C> G, 91C> T] and two
mutations [161C> T, 133 G> C] were identified outside
the protein coding region in the promoter region and 50
untranslated region of exon 1 (Table 2). Three of these five
variants have not been reported previously. None of the
SNPs in intron regions will probably affect splicing, as
assessed by their distant position from the exon-intron
junction and the nucleotide substituted.g phenotypes in the Copenhagen City Heart Study.
High FEV1
(nZ 140)
Low FEV1
smokers
(nZ 122)
Low FEV1
non-smokers
(nZ 118)
No extreme
phenotype
(nZ 9844)
54 1.3 56 1.4 55 1.5 56 0.2
45/55 43/57 46/54 45/55
123 1.4 41 1.5 49 1.6 87 0.2
119 1.3 58 1.4 62 1.5 89 0.2
0.83 0.0 0.56 0.01 0.63 0.02 0.78 0.0
59 100 62 72
8.2 1.3 32 1.7 21 2.3 17 0.2
uestions ‘‘do you have asthma?’’ Chronic Obstructive Pulmonary
sthmatics. Interstitial lung diseaseZ ICD8: 517, ICD10:J84. High
the Copenhagen City Heart Study. Low FEV1 smokersZ the 122
ow FEV1 non-smokersZ the 118 individuals with the lowest FEV1%
Table 2 Genetic variation in the core promoter and exons 1e5 of SFTPC in individuals with extreme lung phenotypes he Copenhagen City Heart Study.
No. of alleles (allele frequency)
Gene
region
Nucleotide
substitution Asthma
(nZ 174)
COPD
(nZ 175)
Idiopathic
interstitial
pneumonia
(nZ 31)
High FEV1
(nZ 140)
Low FEV1
smokers
(nZ 122)
Low FEV1
non-smokers
(nZ 118)
Allel quency
(NCB
data )
AA
residue
Side chain
substitution
Refs. and
SNP ID
numbers
Promoter 271G> A 22 (0.126) 24 (0.137) 3 (0.097) 24 (0.171) 18 (0.148) 19 (0.161) 0.08 rs8192339
Exon 1 161C> T 1 50UTR New
Exon 1 133G> C 1 50UTR rs28438700
Exon 1 92C>G 3 5 1 4 1 3 50UTR New
Exon 1 91C> T 3 5 1 4 1 3 50UTR New
Exon 1 24C>G 1 V8V 30
Exon 1 42G> A 1 P14P 31
IVS1þ 35 IVS1þ 35G> A 22 (0.126) 24 (0.137) 3 (0.097) 24 (0.171) 18 (0.148) 19 (0.161) 0.08 rs8192340
IVS1-21 IVS1-21T> C 87 (0.497) 78 (0.446) 16 (0.516) 56 (0.400) 41 (0.336) 39 (0.331) 0.40 rs13248346
Exon 2 157G> A 1 1 A53T Nonpolar to
polar
New
Exon 2 162G> C 1 L54L New
Exon 2 198G> A 1 E66E New
IVS2þ 14 IVS2þ 14G> A 17 (0.098) 17 (0.097) 2 (0.065) 18 (0.129) 12 (0.098) 15 (0.127) 0.10 rs8192327
Exon 3 288C> T 1 1 2 I96I New
Exon 3 318C> A 1 Y106X Truncation New
Exon 4 413C> A 77 (0.443) 86 (0.491) 9 (0.290) 42 (0.300) 32 (0.262) 40 (0.339) 0.27 T138N Nonpolar to
nonpolar
rs4715
IVS4-8 IVS4-8C> G 71 (0.406) 67 (0.383) 13 (0.419) 46 (0.329) 35(0.287) 45 (0.381) 0,24 rs2070687
Exon 5 557A>G 81 (0.466) 66 (0.377) 11 (0.355) 64 (0.457) 47 (0.385) 41 (0.347) 0.21 N186S Nonpolar to
nonpolar
rs1124
Values represent number of individuals (allele frequency). Nucleotide 1 denotes A in the start codon ATG in exon 1 correspond o base position 159 in mRNA sequence NM_003018.
Variants in bold were subsequently screened for in the Copenhagen City Heart Study and the Copenhagen General Population S .
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Figure 1 Alignment of surfactant protein-C between species. Human preSP-C (NP_00309) and the orthologous murine
(NP_035486) and rat (NP_059038) protein sequences were aligned with the ClustalW program (http://www.ebi.ac.uk/Tools/
clustalw2/). The identified amino acid substitutions are marked in bold. The mature SP-C protein (amino acid 24-58) and the
BRICHOS domain (amino acid 94-197) are underscored.
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In order to determine whether individuals heterozygous for
the A53T and Y106X mutations have lower lung function or
greater risk of asthma, COPD, and interstitial lung disease,
we genotyped the entire Copenhagen City Heart Study
(nZ 10,604) and another large population-based cohort
study, the Copenhagen General Population Study
(nZ 37,337). We identified 36 individuals heterozygous for
the A53T mutation and 3 individuals heterozygous for the
Y106X mutation in the Copenhagen City Heart Study and
Copenhagen General Population Study. The A53T and Y106X
genotype frequencies were in Hardy-Weinberg equilibrium
(Ps 0.93).
The A53T heterozygotes did not differ from non-carriers
in FEV1 % predicted, FVC % predicted, or FEV1/FVC in the
Copenhagen City Heart Study or Copenhagen General
Population Study (all Ps 0.14; Fig. 2). Combining the
Copenhagen City Heart Study and the Copenhagen General
Population Study, A53T heterozygotes had FEV1 % pre-
dicted, FVC % predicted and FEV1/FVC of 90%, 94% and 0.76
compared with 88%, 91% and 0.79 in non-carriers
(Ps> 0.20). The Y106X heterozygotes also did not differ
from non-carriers in FEV1 % predicted, FVC % predicted, or
FEV1/FVC in the Copenhagen City Heart Study or Copen-
hagen General Population Study (Ps 0.47; Fig. 2).
Combining the Copenhagen City Heart Study and the
Copenhagen General Population Study, Y106X heterozy-
gotes had FEV1 % predicted, FVC % predicted and FEV1/FVC
of 91%, 90% and 0.80 compared with 88%, 91% and 0.79 in
non-carriers (Ps> 0.52).
Asthma, Chronic Obstructive Pulmonary Disease
(COPD), and interstitial lung disease by the A53T
and Y106X mutations
A53T heterozygotes had an odds ratio for asthma of 15 (95%
confidence interval: 2.4e87) in the Copenhagen City HeartStudy after adjustment for age, sex, and smoking status
(Fig. 3).
In the Copenhagen General Population Study A53T
heterozygotes had an adjusted odd ratio for asthma of 1.3
(0.5e3.4). When the two studies were combined to achieve
the maximal statistical power, A53T heterozygotes had an
adjusted odd ratio for asthma of 2.2 (1.0e4.9).
A53T heterozygotes had an odds ratio for COPD of 1.0
(0.1e9.1) in the Copenhagen City Heart Study after
adjustment for age, sex, and smoking status. In the
Copenhagen General Population Study A54T heterozygotes
had an adjusted odd ratio for COPD of 0.3 (0.0e2.1). When
the two studies were combined to achieve the maximal
statistical power, A53T heterozygotes had an odd ratio for
COPD of 0.4 (0.1e1.8).
No A53T heterozygotes or Y106X heterozygotes suffered
from interstitial lung disease in the Copenhagen City Heart
Study or Copenhagen General Population Study. No Y106X
heterozygotes had asthma or COPD in any of the two
studies.
Discussion
In order to identify genetic variation in SFTPC affecting lung
function and risk of lung disease in the population, we
screened individuals with extreme pulmonary phenotypes
in the Copenhagen City Heart Study for genetic variation in
the promoter and protein coding regions of SFTPC. We
identified two novel mutations, A53T and Y106X, located in
regions encoding the mature protein and proprotein,
respectively. We subsequently genotyped the entire
Copenhagen City Heart Study as well as an additional large
population-based cohort, the Copenhagen General Pop-
ulation Study. Correlating this genotyping information with
data on lung function and pulmonary disease, we found
that heterozygotes for the A53T and Y106X mutations have
normal lung function and are unaffected by COPD and
interstitial lung disease. We did find an association between
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Figure 2 Lung function for heterozygous carriers of surfactant protein-C mutations in the Copenhagen City Heart Study and the
Copenhagen General Population Study. Exact values for each heterozygous mutation carrier are superimposed on the 5th, 50th,
and 95th percentiles for age as a whole (NZ 47941).
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Figure 3 Risk of asthma (top panel) and chronic obstructive
pulmonary disease (lower panel) in heterozygous carriers of
the A53T mutation. Values represent odds ratios and 95%
confidence intervals. Multiple adjusted models included age,
sex and smoking status.24 CCHS: Copenhagen City Heart Study.
CGPS: Copenhagen General Population Study. Asthma was
defined as ‘‘yes’’ to the question ‘‘do you have asthma?’’
Chronic obstructive pulmonary disease (COPD) was FEV1/
FVC< 0.7 and FEV1% predicted <80%, excl. asthmatics.
Mutations in SP-C and obstructive lung disease 423A53T heterozygozity and increased risk of asthma in the
Copenhagen City Heart Study as well as in the Copenhagen
City Heart Study and the Copenhagen General Population
Study combined.
We report the only second mutation identified within the
mature region of the SP-C protein, the A53T mutation.
While A53T may associate with increased risk of asthma,
the other known mutation in the mature region of SP-C,
P30L, is linked with interstitial lung disease and low SP-C
levels.27 The difference in phenotypic outcome of the two
mutations may be due to the difference in their local-
isation. P30L is located at the cytosolic N-terminal, a posi-
tion shown to be involved in sorting of proSP-C.24e26 In
contrast, the A53T mutation is located within the trans-
membrane domain of SP-C and thus may not affect
processing of the proprotein.
The second novel mutation identified in this study is the
Y106X mutation, which introduces a premature stop codon
in exon 3, thereby truncating most of the C-terminal of
proSP-C and almost the entire BRICHOS domain. Nearly all
previous mutations and deletions in the BRICHOS domain
are linked with interstitial lung disease.11,12 The BRICHOS
variations result in misfolding and subsequent mistargeting
424 M. Bækvad-Hansen et al.of unprocessed proSP-C and may lead to endoplasmatic
stress, cell injury and apoptosis.23,27,28 The Y106X mutation
does not have apparent influence on lung function in this
study, and none of the three mutation carriers identified
suffer from asthma, COPD, or interstitial lung disease.
Thus, the supposedly severe Y106X genotype has no
apparent phenotypic effect.
A previous report supports SP-C could be related to
asthma, as was observed for the A53Tmutation in the present
study. This study found elevated level of SP-C in bron-
choalveolar lavage fluids from asthma patients after allergen
challenge.29 Out of the four surfactant proteins studied,
surfactant protein-C was most closely related to surfactant
dysfunction and the degree of the allergic inflammation.29
The study speculated a potential role of SP-C in asthma could
include protection against loss of biophysical surfactant
function in the terminal airways because SP-C maintains
a stable association of surfactant with the interface and it
permits resistance to surfactant inhibition by invading plasma
proteins.29 It is widely accepted that mutations in surfactant
protein-C are associated with interstitial lung disease. This is
mainly based on family studies and case series. In our studywe
find a possible association between A53T in surfactant
protein-C and elevated risk of asthma. Surfactant protein C
may thus play a role in other pulmonary conditions than
interstitial lung disease. The elevated risk of asthmawas only
significant in the Copenhagen City Heart Study, and the
Copenhagen City Heart Study and Copenhagen General Pop-
ulation Study combined, andwehad80%power todetect odds
ratios of 3.0 for asthmaandof 3.0 for COPD in the Copenhagen
City Heart Study and Copenhagen General Population Study
combined. Our results should thus be interpreted with care
and additional studies are needed to conclusively determine
whether the A53T mutation is associated with asthma.
Our study has the advantages: 1) a resenquencing
strategy, which obviates the inherent biases of selecting
SNPs from databases only, and 2) the two large and well
characterised general populations used to assess the
clinical relevance of the rare mutations identified. Our
study also has potential limitations. Asthma was defined by
a single question, which could be considered a too weak
definition of asthma. However, when the asthma definition
included a confirmation of airway obstruction or was
defined as ‘‘Yes’’ to the question ‘‘does exposure to food,
medicine, flowers, animals or anything else cause
asthma?’’, the analyses were based on up to 39,512 indi-
viduals of the 48,000 participants studied and showed
nonsignificant but similar risk estimates to those presented
in the manuscript (Supplementary Table 2).
In conclusion, we identified two novel mutations in two
conserved regions of the SFTPC gene and show that one of
the novel mutations, A53T may be a risk factor for asthma.
Further research into this area will be required to conclu-
sively determine whether the A53T mutation is associated
with asthma. Individuals that are heterozygous for either of
the two mutations have normal lung function and are
unaffected by COPD and interstitial lung disease.
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